What can we help you find?

Leading the way in transplantation

Filter results for:

Advancements in molecular biology technology allowed the development of promising biomarkers, such as Peripheral blood gene expression profiling (GEP) and cell-free DNA (cfDNA), for minimally invasive characterisation of allograft rejection.

The use of circulating GEP and cfDNA may offer advantages over invasive tissue biopsy as a quantitative measure for detection of transplant rejection and immunosuppression optimisation.

However, there is no standard recognition of the usage of this new technology. As such, ESOT will drive and coordinate a whitepaper about molecular biomarkers for the non-invasive diagnosis of rejection that is aimed at providing a full European landscape and address unmet clinical needs.

Topic Chairs: John Friedewald (Kidney) Marina Berenguer (Liver) & Luciano Potena (Heart)

Steering Committee for Kidney: Dany Anglicheau, Oriol Bestard, John Friedewald, Claire Tinel, Sook Park, Joana Sellares

Steering Committee for Heart: Maria Crespo Leiro, Kiran Khush, Ingvild Birschmann, Javier Segovia, Andriana Nikolova, Annamaria Minervini

Steering Committee for Liver: Amelia Heissheimer, Eleonora de Martin, Valeria Mas, Josh Levitsky, Haseeb Zubair, Alina Lutu, Nabeel Wahid

Steering Committee for Lung: Sean Agbor-Enoh, Robin Vos

 

Heart and Lung

           

Kidney

           

Liver

           

Join our community today!

Learn more